Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVIDENT in metastatic colorectal cancer
2023-510092-62-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate, trastuzumab, alectinib, everolimus, talazoparib and 10 more in colorectal cancer (CRC) (15 cohorts), sponsored by Oslo University Hospital. Primary endpoints: Pre-screening feasibility of profiling and organoid establishment and Objective response rate. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-510092-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510092-62-00.